by fshdfalcon | May 22, 2026 | Special Events
At the kind invitation of Dr. Alberto Malerba, Lecturer in Gene Therapy at the Royal Holloway, University of London, Rajeshri Badiani presented the FSHD UK journey Rajeshri Badiani presented the FSHD UK journey on ‘starting a volunteer group to setting up a formal...
by fshdfalcon | May 22, 2026 | Research News shared by our teams
A new experimental therapy designed to support muscle regeneration has shown encouraging results in a mouse model of facioscapulohumeral muscular dystrophy (FSHD), offering fresh hope for future treatment approaches for the condition. The therapy, known as SAT-3247,...
by fshdfalcon | May 22, 2026 | Clinical Trial & Studies Updates
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
by fshdfalcon | May 22, 2026 | Clinical Trial & Studies Updates
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy
